Revision Bioimplants Global Market Report 2026

Revision bioimplants represent a class of implantable biomedical devices developed to replace, restore, or support previously implanted biological or synthetic materials that have failed, deteriorated, or become unsuitable over time. These implants are applied in secondary or corrective interventions when original implants are compromised due to factors such as wear, loosening, infection, or inadequate biological compatibility.

The primary types of revision bioimplants include metallic bioimplants, polymeric bioimplants, ceramic bioimplants, and composite bioimplants. Metallic bioimplants are implantable devices manufactured from biocompatible metals that are utilized to substitute, support, or repair damaged tissues during revision procedures. These products are offered with fixation approaches such as cemented fixation, cementless fixation, and hybrid fixation. The different applications associated with them include orthopedic surgery, dental surgery, cardiovascular surgery, neurological surgery, and plastic and reconstructive surgery, and they are utilized by various end users including hospitals, specialty clinics, ambulatory surgical centers, and research institutions.

Tariffs are influencing the revision bioimplants market by increasing expenses related to imported biomaterials, titanium alloys, bioactive glass, hydroxyapatite, precision surgical instruments, and specialized manufacturing equipment used in implant production. This is elevating production costs and increasing procedural expenses for revision surgeries, particularly impacting metallic bioimplants, composite implants, and advanced material-based systems used in orthopedic, dental, cardiovascular, and neurological applications. Regions with heavy reliance on imported medical-grade materials and devices, including Asia-Pacific, Europe, and North America, are experiencing supply chain disruptions and procurement challenges. However, tariffs are also encouraging expansion of domestic manufacturing, diversification of regional suppliers, and greater investment in local bioimplant production capabilities, supporting long-term market stability.

The revision bioimplants market size has grown strongly in recent years. It will grow from $3.05 billion in 2025 to $3.33 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to increasing incidence of implant failure and loosening, rising volume of joint replacement procedures, growing prevalence of age-related orthopedic disorders, expansion of reconstructive and corrective surgeries, and increased awareness of advanced revision treatment options.

The revision bioimplants market size is expected to see strong growth in the next few years. It will grow to $4.76 billion in 2030 at a compound annual growth rate (CAGR) of 9.4%. The growth during the forecast period can be linked to increasing demand for long-lasting revision implant solutions, continuous advancements in biocompatible implant materials, rising adoption of minimally invasive revision surgical procedures, growing healthcare expenditure on complex surgical interventions, and expansion of the patient population requiring secondary implant surgeries. Key trends expected in the forecast period include greater adoption of revision-specific bioimplant designs, rising demand for durable and wear-resistant implant systems, increasing use of patient-matched implants in corrective surgeries, expansion of advanced biomaterial applications in revision procedures, and stronger focus on infection-resistant implant technologies.

The increasing incidence of chronic and degenerative disorders is expected to drive the growth of the revision bioimplants market going forward. Chronic and degenerative disorders refer to long-term progressive medical conditions such as cardiovascular diseases, osteoarthritis, osteoporosis, and spinal disorders that gradually impair body structure and organ function over time. The rising prevalence of chronic and degenerative disorders is increasing due to the expanding elderly population, which is at a higher risk of cardiovascular complications, tissue degeneration, and implant failure. Revision bioimplants assist in the treatment of chronic and degenerative disorders by replacing failed implants, restoring physiological function, and enhancing long-term patient outcomes. For instance, in January 2026, according to the American Heart Association, a US-based nonprofit cardiovascular health organization, cardiovascular disease caused 915,973 deaths in the United States in 2023, compared to 941,652 deaths in 2022, while coronary heart disease accounted for 349,470 deaths in 2023 compared to 371,506 deaths in 2022. Therefore, the increasing incidence of chronic and degenerative disorders is driving the growth of the revision bioimplants market.

Key companies operating in the revision bioimplants market are focusing on the adoption of personalized and 3D-printed revision implants, such as manufacturing patient-specific orthopedic implants, to improve anatomical fit, enhance implant stability, and reduce surgical complications. Manufacturing in the revision bioimplants market refers to the process of designing and producing customized implants using advanced technologies such as 3D printing and digital imaging to match individual patient anatomy and complex bone defects. For example, in February 2024, Smith+Nephew, a UK-based medical technology company, launched the AETOS Shoulder System for shoulder arthroplasty procedures. The system features a platform shoulder design with personalized implant positioning, 3D pre-operative planning capabilities, and augmented glenoid technology that supports precise implant placement and improved fixation in complex revision surgeries. The launch strengthens the adoption of patient-specific and digitally enabled implant solutions across the revision bioimplants market.

In May 2023, Zimmer Biomet Holdings, Inc., a US-based company specializing in musculoskeletal healthcare solutions, orthopedic implants, and robotic-assisted surgical technologies, acquired OSSIS for an undisclosed value. Through this acquisition, Zimmer Biomet intended to enhance its revision biologics and implant portfolio by broadening its expertise in patient-specific 3D-printed orthopedic implants and improving offerings for complex revision hip reconstruction procedures, tumor-related cases, and trauma surgeries. OSSIS is a New Zealand-based company that develops patient-specific 3D-printed titanium implants and orthopedic reconstruction solutions tailored for complex revision surgeries and customized bone replacement needs.

Major companies operating in the revision bioimplants market are Johnson & Johnson, Stryker Corporation, Zimmer Biomet Holdings Inc., Medtronic plc, Smith & Nephew plc, Globus Medical Inc., B. Braun Melsungen AG, Straumann Holding AG, Enovis Corporation, Integra LifeSciences Holdings Corporation, W. L. Gore & Associates Inc., Orthofix Medical Inc., MicroPort Scientific Corporation, Corbion N.V., LifeNet Health Inc., Cook Medical LLC, DSM Biomedical B.V., Exactech Inc., Invibio Ltd., Paragon 28 Inc., Peter Brehm GmbH, Maxx Orthopedics Inc., Implants International Ltd.

North America was the dominant region in the revision bioimplants market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in revision bioimplants report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the revision bioimplants market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The revision bioimplants consists of sales of revision joint implants, revision knee implants, revision hip implants, spinal revision implants, dental revision implants, trauma fixation implants, bone graft substitutes, bioresorbable implants, and surgical meshes. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The revision bioimplants market research report is one of a series of new reports from The Business Research Company that provides revision bioimplants market statistics, including revision bioimplants industry global market size, regional shares, competitors with a revision bioimplants market share, detailed revision bioimplants market segments, market trends and opportunities, and any further data you may need to thrive in the revision bioimplants industry. This revision bioimplants market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Revision Bioimplants Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses revision bioimplants market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for revision bioimplants ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The revision bioimplants market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type Of Bioimplant: Metallic Bioimplants; Polymeric Bioimplants; Ceramic Bioimplants; Composite Bioimplants
• 2) By Fixation Method: Cemented Fixation; Cementless Fixation; Hybrid Fixation
• 3) By Application: Orthopedic Surgery; Dental Surgery; Cardiovascular Surgery; Neurological Surgery; Plastic And Reconstructive Surgery
• 4) By End User: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Research Institutions
• Subsegments:
• 1) By Metallic Bioimplants: Stainless Steel Implants; Titanium Based Implants; Cobalt Chromium Implants; Magnesium Based Implants
• 2) By Polymeric Bioimplants: Silicone Implants; Polyethylene Implants; Polyether Ether Ketone Implants; Polylactic Acid Implants
• 3) By Ceramic Bioimplants: Alumina Implants; Zirconia Implants; Calcium Phosphate Implants; Hydroxyapatite Implants
• 4) By Composite Bioimplants: Polymer Ceramic Composites; Carbon Fiber Composites; Hydroxyapatite Polymer Composites; Bioactive Glass Composites
• Companies Mentioned: Johnson & Johnson; Stryker Corporation; Zimmer Biomet Holdings Inc.; Medtronic plc; Smith & Nephew plc; Globus Medical Inc.; B. Braun Melsungen AG; Straumann Holding AG; Enovis Corporation; Integra LifeSciences Holdings Corporation; W. L. Gore & Associates Inc.; Orthofix Medical Inc.; MicroPort Scientific Corporation; Corbion N.V.; LifeNet Health Inc.; Cook Medical LLC; DSM Biomedical B.V.; Exactech Inc.; Invibio Ltd.; Paragon 28 Inc.; Peter Brehm GmbH; Maxx Orthopedics Inc.; Implants International Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.